Barclays Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) but lowered the price target from $148 to $90.
August 04, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Overweight rating on Intellia Therapeutics but lowered the price target from $148 to $90.
The lowering of the price target by Barclays from $148 to $90 indicates a potential decrease in the stock's value. However, the maintained Overweight rating suggests that Barclays still sees the stock as a good investment, albeit at a lower price point. This could lead to a short-term decrease in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100